Good news for younger children suffering from the uncommon but debilitating gastrointestinal condition eosinophilic esophagitis (EoE). A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo. Data from this trial led to a January US Food and Drug Administration (FDA) approval of the anti-inflammatory …
